Abstract 2398P
Background
FGFR3 is associated to proliferation, differentiation and cellular growth. FGFR3 alterations are present in 25% of patients (pts) with MUC and FGFR3 inhibition is an active targeted therapy. However, the role of FGFR3 alterations in patients’ clinical outcomes and response to conventional treatment is unclear and no pre-clinical evidence is available.
Methods
Unicenter retrospective study was performed to explore the correlation between FGFR3 alterations and response rate (ORR), progression free survival (PFS) and overall survival (OS) to platinum-based therapies or immunotherapy. Enrolled pts were diagnosed with muscle-invasive urothelial cancer (MIUC) between 2/2009- 3/2022 at Clinic Hospital of Barcelona, Spain. All were screened for FGFR-3 alterations using next-generation sequencing, qualitative real-time polymerase chain reaction-based assays or RNA-ISH in tumour and/or blood. Demographics, pathology, treatments outcomes were collected retrospectively.
Results
189 pts with MIUC were included: 74.6% were men, median age was 68.5 (37.6-89.7y). Clinical stage at diagnosis was: 10% II, 44% III, 46% IV. Median follow-up since metastatic disease diagnosis was 16.2 months (0.3-91m). 77% of pts had died at data cut-off. 25.4% had FGFR3 alterations (mutation= 36; fusion= 6; double alteration= 3; RNA-ISH amplification =3). FGFR3 altered (FGFR3-alt) tumours were enriched with papillary histology compared with FGFR3 wild type (FGFR3-wt) (33 vs 11%, p<0.05). No statistical differences were detected in other baseline characteristics. 66.5% (N=113) pts received 1st-line platinum-based chemotherapy (1st PT) and 58% (N=69) 2nd-line immunotherapy (2nd IO). No statistically significant differences were detected in OS (15.2 vs 17.5m), PFS (5.6 vs 7.2m), ORR (62 vs 55%) for pts treated with 1st PT according to FGFR3-alt or FGFR3-wt. In 2nd IO, FGFR3-alt had less ORR than FGFR3-wt (9 vs 41%)(p=0.32) and no statistically significant differences in OS (9.7 vs 12.1m) or PFS (3 vs 3.9m) were observed.
Conclusions
In our cohort, FGFR3 alterations are neither predictive nor prognostic for 1st-line platinum or 2nd-line IO. Further investigation is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
L. Ferrer-Mileo: Financial Interests, Personal, Other, speaker, travel accommodation: Pfizer; Financial Interests, Personal, Invited Speaker, speaker, travel accommodation: Kyowa Kirin; Financial Interests, Personal, Invited Speaker, Speaker: Ipsen, Janssen. C. Aversa: Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Institutional, Invited Speaker: Janssen, BMS; Other, Travel funding: Janssen. B. Mellado Gonzalez: Financial Interests, Personal, Other, Research Grant/Funding (Self), Speaker Bureau, Travel accommodation: Jansen, Roche, Astellas, Sanofi, Bayeri; Financial Interests, Personal, Other, Speaker Bureau, Travel accommodation: Pfizer; Financial Interests, Personal, Other, Travel accommodation, Speaker Bureau: Ipsen; Financial Interests, Personal, Other, Speaker Bureau: BMS. O. Reig Torras: Financial Interests, Personal, Invited Speaker: Pfizer, BMS, Ipsen. All other authors have declared no conflicts of interest.
Resources from the same session
2380P - Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)
Presenter: Nicolas Sayegh
Session: Poster session 24
2381P - Perceived unmet needs and challenges faced by patients with advanced bladder cancer (aBC) and their caregivers: Results of a social media listening (SML) study conducted in 5 European countries
Presenter: Stephane Schuck
Session: Poster session 24
2382P - EBANO study: Clinical characteristics, treatment patterns and survival results in patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in northern Spain
Presenter: Ricardo Fernandez-Rodriguez
Session: Poster session 24
2383P - Stereotactic body radiotherapy (SBRT) of patients with oligometastatic urothelial cancer (UC): A single institution experience
Presenter: Faith Jawdat
Session: Poster session 24
2384P - Platinum rechallenge in the era of immune checkpoint inhibitor in locally advanced/metastatic urothelial carcinoma: Multicenter retrospective study
Presenter: Eojin Kim
Session: Poster session 24
2385P - Long-term survival upon anti-PD-(L)1 monotherapy in metastatic urothelial cancer (mUC): A multicenter retrospective study
Presenter: Chantal Stockem
Session: Poster session 24
2386P - Factors associated with not receiving systemic treatment (tx) in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany
Presenter: Günter Niegisch
Session: Poster session 24
2387P - Avelumab first-line maintenance (1LM) for locally advanced or metastatic urothelial carcinoma (la/mUC): Treatment (tx) patterns and real-world (rw) outcomes in the US
Presenter: Kenneth Carson
Session: Poster session 24
2390P - Correlation between overall survival and bladder-intact event-free survival in cystectomy-ineligible/refusal muscle-invasive bladder cancer patients in Sweden
Presenter: Kelvin Kwok
Session: Poster session 24